Work

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4024

Authors: Yu Aoki, Izuma Nakayama, Masashi Wakabayashi, Hiroki Hara, Mitsuhiro Furuta, Shota Fukuoka, Hirokazu Shoji, Keiko Minashi, Yu Komura, Takashi Ikeno, Akihiro Sato, Nozomu Fuse, Naoya Sakamoto, Takeshi Kuwata, Takeo Fujita, Takahiro Kinoshita, Kohei Shitara

Institutions: National Cancer Center Hospital East, Saitama Prefecture, Saitama Cancer Center, Kanagawa Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, National Cancer Center Hospital, Chiba Cancer Center, National Cancer Centre Japan

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Daiichi Sankyo Europe

OpenAlex ID: W7162518271

Cites:

Cited by:

Related to: